FOXA1 and breast carcinoma: Since the aberrant DNA hypomethylation of promoter regions is one of the mechanisms underlying the aberrant expression of oncogenes in tumors, and the FOXA1 promoter is mostly methylated in ER− tumors, we speculate that FOXA1 functions principally as an oncogene in ER+ breast cancer.